{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T16:57:20Z","timestamp":1758905840553},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2010,4,21]],"date-time":"2010-04-21T00:00:00Z","timestamp":1271808000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1007\/s12032-010-9529-9","type":"journal-article","created":{"date-parts":[[2010,4,20]],"date-time":"2010-04-20T16:41:52Z","timestamp":1271781712000},"page":"835-839","source":"Crossref","is-referenced-by-count":12,"title":["Knockdown of SOD1 sensitizes the CD34+ CML cells to imatinib therapy"],"prefix":"10.1007","volume":"28","author":[{"given":"Li","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siyong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanlan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guohui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dandan","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingmin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,4,21]]},"reference":[{"issue":"4760","key":"9529_CR1","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1126\/science.3460176","volume":"233","author":"Y Ben-Neriah","year":"1986","unstructured":"Ben-Neriah Y, Daley GQ, Mes-Masson AM, Witte ON, Baltimore D. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr\/abl hybrid gene. Science. 1986;233(4760):212\u20134.","journal-title":"Science"},{"issue":"5","key":"9529_CR2","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2(5):561\u20136.","journal-title":"Nat Med"},{"issue":"5","key":"9529_CR3","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1182\/blood.V83.5.1179.1179","volume":"83","author":"A McGahon","year":"1994","unstructured":"McGahon A, et al. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood. 1994;83(5):1179\u201387.","journal-title":"Blood"},{"issue":"3","key":"9529_CR4","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3109\/10428190903518295","volume":"51","author":"DJ Deangelo","year":"2010","unstructured":"Deangelo DJ, Attar EC. Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice. Leuk Lymphoma. 2010;51(3):363\u201375.","journal-title":"Leuk Lymphoma"},{"key":"9529_CR5","doi-asserted-by":"crossref","unstructured":"Hughes TP, Branford S. Monitoring disease response to tyrosine kinase inhibitor therapy in CML. Hematol Am Soc Hematol Educ Prog. 2009:477\u2013487.","DOI":"10.1182\/asheducation-2009.1.477"},{"issue":"6","key":"9529_CR6","doi-asserted-by":"crossref","first-page":"530","DOI":"10.2174\/138945009788488468","volume":"10","author":"M Breccia","year":"2009","unstructured":"Breccia M, Alimena G. Nilotinib therapy in chronic myelogenous leukemia: the strength of high selectivity on BCR\/ABL. Curr Drug Targets. 2009;10(6):530\u20136.","journal-title":"Curr Drug Targets"},{"issue":"5","key":"9529_CR7","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrc2126","volume":"7","author":"E Weisberg","year":"2007","unstructured":"Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer. 2007;7(5):345\u201356.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"9529_CR8","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/j.leukres.2008.04.012","volume":"32","author":"A Gontarewicz","year":"2008","unstructured":"Gontarewicz A, et al. PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases. Leuk Res. 2008;32(12):1857\u201365.","journal-title":"Leuk Res"},{"issue":"4","key":"9529_CR9","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/leu.2008.364","volume":"23","author":"F Belloc","year":"2009","unstructured":"Belloc F, et al. The stem cell factor-c-KIT pathway must be inhibited to enable apoptosis induced by BCR-ABL inhibitors in chronic myelogenous leukemia cells. Leukemia. 2009;23(4):679\u201385.","journal-title":"Leukemia"},{"issue":"4","key":"9529_CR10","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/sj.leu.2405086","volume":"22","author":"H Konig","year":"2008","unstructured":"Konig H, et al. Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors. Leukemia. 2008;22(4):748\u201355.","journal-title":"Leukemia"},{"issue":"2","key":"9529_CR11","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.cell.2007.01.003","volume":"128","author":"Z Tothova","year":"2007","unstructured":"Tothova Z, et al. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell. 2007;128(2):325\u201339.","journal-title":"Cell"},{"issue":"7281","key":"9529_CR12","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nature08734","volume":"463","author":"K Naka","year":"2010","unstructured":"Naka K, et al. TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature. 2010;463(7281):676\u201380.","journal-title":"Nature"},{"issue":"11","key":"9529_CR13","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1089\/ars.2008.2142","volume":"10","author":"S Ghaffari","year":"2008","unstructured":"Ghaffari S. Oxidative stress in the regulation of normal and neoplastic hematopoiesis. Antioxid Redox Signal. 2008;10(11):1923\u201340.","journal-title":"Antioxid Redox Signal"},{"issue":"11","key":"9529_CR14","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1089\/ars.2008.2114","volume":"10","author":"K Naka","year":"2008","unstructured":"Naka K, Muraguchi T, Hoshii T, Hirao A. Regulation of reactive oxygen species and genomic stability in hematopoietic stem cells. Antioxid Redox Signal. 2008;10(11):1883\u201394.","journal-title":"Antioxid Redox Signal"},{"issue":"3","key":"9529_CR15","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/sj.emboj.7601528","volume":"26","author":"CK Bruns","year":"2007","unstructured":"Bruns CK, Kopito RR. Impaired post-translational folding of familial ALS-linked Cu, Zn superoxide dismutase mutants. EMBO J. 2007;26(3):855\u201366.","journal-title":"EMBO J"},{"issue":"5\u20136","key":"9529_CR16","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1089\/ars.2006.8.847","volume":"8","author":"Y Furukawa","year":"2006","unstructured":"Furukawa Y, O\u2019Halloran TV. Posttranslational modifications in Cu, Zn-superoxide dismutase and mutations associated with amyotrophic lateral sclerosis. Antioxid Redox Signal. 2006;8(5\u20136):847\u201367.","journal-title":"Antioxid Redox Signal"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-010-9529-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-010-9529-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-010-9529-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T22:16:36Z","timestamp":1591222596000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-010-9529-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,21]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["9529"],"URL":"https:\/\/doi.org\/10.1007\/s12032-010-9529-9","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,21]]}}}